In this study, we briefly assessed the prognostic value and immunological function of MTHFD2 in pan-carcinoma, and further investigated its relationship with TME, molecular subtypes, and immunotherapy response in BLCA in detail. This evidence concerns the gene MTHFD2 and bladder transitional cell carcinoma.